FDA Inspection
Wyeth BioPharma Division of Wyeth Pharmaceuticals LLCWyeth BioPharma Division of Wyeth Pharmaceuticals LLC – FDA Inspection, Apr 8, 2026
Record Details
This FDA Inspection record concerns Wyeth BioPharma Division of Wyeth Pharmaceuticals LLC, with an inspection on April 8, 2026, issued by the New England District Office, covering human drugs.
- Inspection Date
- April 8, 2026
- Product Type
- Human Drugs
View Company Profile
ID · c5b9683d-dfc5-496a-afe9-353614bb2207
Inspection Facts
- Inspection number
- 1311392
- FDA center
- Human Drugs
- Outcome
- Form 483 issued
Other FDA inspections of Wyeth BioPharma Division of Wyeth Pharmaceuticals LLC
16| Date | Classification | Office | Project area |
|---|---|---|---|
| August 6, 2026 | Not classified | New England District Office | |
| February 11, 2026 | NAI | Human Cellular, Tissue, and Gene Therapies | |
| October 13, 2023 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| September 19, 2023 | VAI | Center for Biologics Evaluation and Research | Blood and Blood Products |
| May 3, 2019 | Not classified | New England District Office |
Other documents for Wyeth BioPharma Division of Wyeth Pharmaceuticals LLC
- FDA Inspection 1331288 - 2026-08-06
- FDA Inspection 1304580 - 2026-02-11
- FDA Inspection 1223617 - 2023-10-13
- FDA Inspection 1218069 - 2023-09-19
- FDA Inspection 1092777 - 2019-05-03
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.